CN1145627C - 吡唑并[4,3-d]嘧啶类 - Google Patents

吡唑并[4,3-d]嘧啶类 Download PDF

Info

Publication number
CN1145627C
CN1145627C CNB008137366A CN00813736A CN1145627C CN 1145627 C CN1145627 C CN 1145627C CN B008137366 A CNB008137366 A CN B008137366A CN 00813736 A CN00813736 A CN 00813736A CN 1145627 C CN1145627 C CN 1145627C
Authority
CN
China
Prior art keywords
methyl
pyrazolo
propyl
pyrimidin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008137366A
Other languages
English (en)
Chinese (zh)
Other versions
CN1377357A (zh
Inventor
��R��Լ��˹
R·约纳斯
��Τ����˹
H·－M·埃根韦勒
P·舍林
M·克里斯塔德勒
N·贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1377357A publication Critical patent/CN1377357A/zh
Application granted granted Critical
Publication of CN1145627C publication Critical patent/CN1145627C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB008137366A 1999-09-06 2000-08-24 吡唑并[4,3-d]嘧啶类 Expired - Fee Related CN1145627C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19942474A DE19942474A1 (de) 1999-09-06 1999-09-06 Pyrazolo[4,3-d]pyrimidine
DE19942474.8 1999-09-06

Publications (2)

Publication Number Publication Date
CN1377357A CN1377357A (zh) 2002-10-30
CN1145627C true CN1145627C (zh) 2004-04-14

Family

ID=7920966

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008137366A Expired - Fee Related CN1145627C (zh) 1999-09-06 2000-08-24 吡唑并[4,3-d]嘧啶类

Country Status (23)

Country Link
US (1) US6777419B1 (https=)
EP (1) EP1210349B1 (https=)
JP (1) JP4975921B2 (https=)
KR (1) KR20020025253A (https=)
CN (1) CN1145627C (https=)
AR (1) AR025569A1 (https=)
AT (1) ATE231866T1 (https=)
AU (1) AU773878B2 (https=)
BR (1) BR0013781A (https=)
CA (1) CA2384037C (https=)
CZ (1) CZ294587B6 (https=)
DE (2) DE19942474A1 (https=)
DK (1) DK1210349T3 (https=)
ES (1) ES2189766T3 (https=)
HU (1) HUP0202624A3 (https=)
MX (1) MXPA02002383A (https=)
NO (1) NO20021083D0 (https=)
PL (1) PL353366A1 (https=)
PT (1) PT1210349E (https=)
RU (1) RU2249594C2 (https=)
SK (1) SK3132002A3 (https=)
WO (1) WO2001018004A2 (https=)
ZA (1) ZA200202653B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031584A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
EP1343506A1 (de) * 2000-12-19 2003-09-17 MERCK PATENT GmbH Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
DE10103647A1 (de) * 2001-01-27 2002-08-01 Merck Patent Gmbh Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005011784D1 (de) * 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
BRPI0609225A2 (pt) * 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
MX363696B (es) * 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
MX2020006174A (es) 2017-12-14 2022-09-27 H Lundbeck As Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US10766893B2 (en) * 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256650A (en) * 1989-03-29 1993-10-26 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
DE10103647A1 (de) * 2001-01-27 2002-08-01 Merck Patent Gmbh Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates

Also Published As

Publication number Publication date
PT1210349E (pt) 2003-06-30
CN1377357A (zh) 2002-10-30
DE19942474A1 (de) 2001-03-15
WO2001018004A2 (de) 2001-03-15
AU773878B2 (en) 2004-06-10
KR20020025253A (ko) 2002-04-03
EP1210349B1 (de) 2003-01-29
DK1210349T3 (da) 2003-05-19
WO2001018004A3 (de) 2001-08-09
JP4975921B2 (ja) 2012-07-11
NO20021083L (no) 2002-03-05
CZ294587B6 (cs) 2005-02-16
HUP0202624A3 (en) 2004-11-29
NO20021083D0 (no) 2002-03-05
EP1210349A2 (de) 2002-06-05
DE50001191D1 (de) 2003-03-06
CZ2002736A3 (cs) 2002-05-15
ZA200202653B (en) 2003-09-23
ATE231866T1 (de) 2003-02-15
SK3132002A3 (en) 2002-07-02
US6777419B1 (en) 2004-08-17
JP2003508534A (ja) 2003-03-04
HUP0202624A2 (hu) 2002-12-28
ES2189766T3 (es) 2003-07-16
MXPA02002383A (es) 2002-09-02
BR0013781A (pt) 2002-05-14
RU2249594C2 (ru) 2005-04-10
CA2384037C (en) 2009-10-13
AR025569A1 (es) 2002-12-04
AU7279300A (en) 2001-04-10
CA2384037A1 (en) 2001-03-15
PL353366A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
CN1145627C (zh) 吡唑并[4,3-d]嘧啶类
CN1138780C (zh) 噻吩并嘧啶类
CN1142936C (zh) 具有磷酸二酯酶-v抑制作用的稠合噻吩并嘧啶及其制备方法和用途
CN1038131C (zh) 吡咯并嘧啶衍生物和其制备中间体及含其的药物组合物和用途
CN1198807C (zh) 作为环加氧酶－2抑制剂的5－芳基－1h－1,2,4－三唑化合物及含有它们的药物组合物
CN1063446C (zh) 作为促性腺激素释放激素拮抗剂的噻吩并吡啶衍生物
CN1474693A (zh) 噻吩并嘧啶的应用
CN1045088C (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1555374A (zh) 新的吡啶取代的吡唑并吡啶衍生物
CN1882591A (zh) 具有PDE－5抑制活性的5,7－二氨基吡唑并[4,3－d]嘧啶
CN1144806C (zh) 噻吩并嘧啶化合物
CN1227554A (zh) 取代的6,5－杂二环衍生物
CN1348453A (zh) 嘧啶并[6,1－a] 异喹啉－4－酮衍生物
CN1280292C (zh) 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
CN1305465A (zh) 芳基链烷酰基哒嗪化合物
CN1032361C (zh) 咪唑并哒嗪化合物的制备方法
CN1610683A (zh) 作为磷酸酶抑制剂的嘧啶并三嗪
CN1123280A (zh) 新型吡咯并咔唑衍生物
CN1329613A (zh) 新的化合物
CN1665508A (zh) 吡唑并[4,3－d]嘧啶类化合物的应用
CN1483035A (zh) 氨磺酰基噻吩并嘧啶
CN1014058B (zh) 制备2-吡咯烷酮衍生物的方法
CN1479619A (zh) 吡唑并[4,3-d]嘧啶类化合物的用途
CN1489467A (zh) 含吡唑并[4,3-d]嘧啶和内皮素受体拮抗剂或者噻吩并嘧啶和内皮素受体拮抗剂的药物制剂
CN1481242A (zh) 含噻吩并嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1050685

Country of ref document: HK